- Home
- Publications
- Publication Search
- Publication Details
Title
Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL
Authors
Keywords
-
Journal
BONE MARROW TRANSPLANTATION
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-11-24
DOI
10.1038/s41409-020-01134-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Repeat Infusions of CD19 CAR-T Cells: Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival
- (2020) Jordan Gauthier et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Feasibility and efficacy of CD19-targeted CAR-T cells with concurrent ibrutinib for CLL after ibrutinib failure
- (2020) Jordan Gauthier et al. BLOOD
- CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
- (2020) Nirali N. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- (2020) Michael Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP)
- (2020) Robert David Sandler et al. Frontiers in Immunology
- Intrathecal chemotherapy for management of steroid-refractory CAR T-cell–associated neurotoxicity syndrome
- (2020) Nirav N. Shah et al. Blood Advances
- Clinical efficacy of anakinra to mitigate CAR T-cell therapy–associated toxicity in large B-cell lymphoma
- (2020) Paolo Strati et al. Blood Advances
- Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2
- (2020) Michael Wang et al. Journal for ImmunoTherapy of Cancer
- Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR-T cells
- (2019) Kevin A. Hay et al. BLOOD
- Early Administration of Tocilizumab (Toci) for the Prevention of Grade 4 Cytokine Release Syndrome (CRS) after CD19-directed CAR T-cell Therapy (CTL019)
- (2019) S. Kadauke et al. CYTOTHERAPY
- CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia
- (2019) Jing Pan et al. LEUKEMIA
- Toxicity and Response following CD19-specific CAR T cells in pediatric/young adult relapsed/refractory B-ALL
- (2019) Kevin J. Curran et al. BLOOD
- Efficacy and Safety of CAR19/22 T-cell "Cocktail" Therapy in Patients with Refractory/ Relapsed B-Cell Malignancies
- (2019) Na Wang et al. BLOOD
- Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy
- (2019) Rebecca A. Gardner et al. BLOOD
- Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia
- (2019) Noelle V. Frey et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia
- (2019) Ivetta Danylesko et al. Current Research in Translational Medicine
- Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques
- (2018) Anandani Nellan et al. BLOOD
- Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
- (2018) David Porter et al. Journal of Hematology & Oncology
- Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
- (2018) Margherita Norelli et al. NATURE MEDICINE
- CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
- (2018) Theodoros Giavridis et al. NATURE MEDICINE
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy
- (2018) Jordan Gauthier et al. Current Research in Translational Medicine
- Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia
- (2018) Elad Jacoby et al. AMERICAN JOURNAL OF HEMATOLOGY
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Ibrutinib treatment improves T cell number and function in CLL patients
- (2017) Meixiao Long et al. JOURNAL OF CLINICAL INVESTIGATION
- High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients
- (2017) J Pan et al. LEUKEMIA
- Modeling continuous response variables using ordinal regression
- (2017) Qi Liu et al. STATISTICS IN MEDICINE
- Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
- (2017) Juliane Gust et al. Cancer Discovery
- 32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part One
- (2017) Journal for ImmunoTherapy of Cancer
- Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives
- (2017) J. Gauthier et al. Current Research in Translational Medicine
- Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
- (2016) Joseph A. Fraietta et al. BLOOD
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
- (2016) Cameron J. Turtle et al. JOURNAL OF CLINICAL INVESTIGATION
- Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms
- (2016) M Ruella et al. LEUKEMIA
- Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
- (2016) D. T. Teachey et al. Cancer Discovery
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo
- (2015) D Sommermeyer et al. LEUKEMIA
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
- (2014) M. L. Davila et al. Science Translational Medicine
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now